Harvard

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting.

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

Physical activity performed in the afternoon could yield a greater reduction in HbA1c than physical activity during other times in the day, according to an analysis of data from the Look AHEAD trial published in Diabetes Care.

An artificial intelligence tool developed at Harvard Medical School and National Cheng Kung University in Taiwan correctly predicted the aggressiveness of colorectal cancer.

Development and use of oral chemotherapy medications has increased substantially over the past decade, offering many patients with cancer a more convenient and less stressful treatment option.

Comparing a virtual care team strategy with usual care for prescribing guideline-recommended HF therapies.

President Joe Biden today announced his intention to nominate NCI director Monica M. Bertagnolli, MD, FACS, FASCO, as director of the NIH.

SEATTLE — Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers.

DESTIN, Fla. — Managing expectations about efficacy is critical for patients with rheumatic diseases using cannabinoid products for pain, sleep or other complications, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

Advances in pediatric cancer research and treatment over the past 50 years have led to dramatic improvements in survival outcomes for this vulnerable population.